The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The Economist explores potential uses of synthetic biology to alter what proteins are produced.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
NPR reports on companies' efforts to develop genetically modified bacteria to treat disease.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.